The skeletal muscle-tissue-specific insulin response and impairment in insulin-resistant mice and humans emphasize the clinical relevance of REPS1 as a potential therapeutic target for diseases characterized with insulin resistance, such as T2D. This evidence concerns the gene REPS1 and Insulin resistance.